Brief: Oculis Holding Says OCS-01 Eye Drop Met Both Primary Endpoints In Phase 3 Optimize Trial

Oculis Holding AG

08/08/2023 11:44

Aug 8 (Reuters) - Oculis Holding AG  CR5.F :
    * OCS-01, FIRST INVESTIGATIONAL EYE DROP FOR FRONT AND BACK
OF THE
EYE, MET BOTH PRIMARY ENDPOINTS IN PHASE 3 OPTIMIZE TRIAL WITH A
ONCE DAILY REGIMEN FOR THE TREATMENT OF INFLAMMATION AND PAIN
FOLLOWING CATARACT SURGERY
    * OCULIS HOLDING - ONCE DAILY OCS-01 MEETS PRIMARY ENDPOINTS
DEMONSTRATING SUPERIOR REDUCTION IN INFLAMMATION, PAIN VERSUS.
VEHICLE AFTER CATARACT SURGERY
    * OCULIS HOLDING AG - OCS-01 WAS WELL TOLERATED WITH A
FAVORABLE
SAFETY PROFILE.

Source text for Eikon:  ID:nGNXb5lp8 
Further company coverage:  CR5.F 

 ((Reuters.Briefs@thomsonreuters.com;))